CO5590958A2 - Inhibidores no nucleosidos de la traqnscriptasa inversa - Google Patents

Inhibidores no nucleosidos de la traqnscriptasa inversa

Info

Publication number
CO5590958A2
CO5590958A2 CO05062907A CO05062907A CO5590958A2 CO 5590958 A2 CO5590958 A2 CO 5590958A2 CO 05062907 A CO05062907 A CO 05062907A CO 05062907 A CO05062907 A CO 05062907A CO 5590958 A2 CO5590958 A2 CO 5590958A2
Authority
CO
Colombia
Prior art keywords
aryl groups
carbocycles
amido
alkyl
compounds
Prior art date
Application number
CO05062907A
Other languages
English (en)
Inventor
Simoneau Bruno
Christiane Yoakim
Anne-Marie Faucher
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of CO5590958A2 publication Critical patent/CO5590958A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

1.- Uso de un compuesto de fórmula 1 para fabricar un medicamento para tratar o prevenir una infección del VIH que comprende administrar a un humano infectado una cantidad terapéuticamente eficaz de dicho compuesto de fórmula 1: Ar1-X-W-Ar2 (1)en la que Ar1 es(i) un heterociclo aromático de 5 ó 6 átomos que contiene de 1 a 4 heteroátomos que se seleccionan entre N, O o S; dicho heterociclo está opcionalmente sustituido con alquilo(C1-4), cicloalquilo(C3-7), cicloalquil(C3-7)-alquil(C1-3)-, en el que dicho alquilo, cicloalquilo o cicloalquilalquilo puede estar monosustituido con -OH; y/o fenilo cuando el heterociclo contiene de 1 a 3 átomos de N; en cualquier caso, el citado heterociclo está opcionalmente sustituido con:fenilo, fenilmetilo, heterociclo aromático de 5 ó 6 átomos, fusión fenil(carbociclo saturado o insaturado de 5 ó 6 átomos), fusión fenil-(carbociclo saturado o insaturado de 5 ó 6 átomos)}metilo, o fusión fenil-(heterociclo aromático de 5 ó 6 átomos); cada uno de los mencionados fenilo, fenilmetilo, heterociclo aromático, fusión fenil-carbociclo, fusión fenil-(carbociclo)metilo o fusión fenil-heterociclo aromático está, a su vez, opcionalmente sustituido, con 1 a 3 sustituyentes que se seleccionan independientemente entre:alquilo(C1-6), cicloalquilo(C3-7), cicloalquil(C3-7)-alquilo(C1-3), alquenilo(C2-6), O-alquilo(C1-4), S-alquilo(C1-4), halo, CF3, OCF3, OH, NO2, CN, fenilo opcionalmente sustituido con alquilo(C1-6) o nitro, fenilmetilo opcionalmente sustituido con alquilo(C1-6) o nitro, SO2NH2, SO2-alquilo(C1-4), C(O)NH2, C(O)OR1, NR2R3, morfolino o 1-pirrolilo, en la que R1 es H o alquilo(C1-4), y en la que R2 y R3 cada uno independientemente es H o alquilo(C1-4); en la que dichos sustituyentes son estéricamente compatibles; o(ii) carbociclo saturado o insaturado de 5 ó 6 átomos que está sustituido con fenilo o naftilo, dicho carbociclo saturado o insaturado, o el fenilo o el naftilo opcionalmente sustituidos con los mismos 1 a 3 sustituyentes como se define para los sustituyentes en la sección (i); o (iii) bencimidazol opcionalmente N-sustituido con fenilo o una fusión fenilcarbociclo como se definió más arriba;X es un heteroátomo que se selecciona entre O, S, SO, SO2 o NR4, en el que R4 es H o alquilo(C1-4); o X es un enlace de valencia o CR4AR4B, ...
CO05062907A 2002-12-04 2005-06-27 Inhibidores no nucleosidos de la traqnscriptasa inversa CO5590958A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43079602P 2002-12-04 2002-12-04

Publications (1)

Publication Number Publication Date
CO5590958A2 true CO5590958A2 (es) 2005-12-30

Family

ID=32469533

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05062907A CO5590958A2 (es) 2002-12-04 2005-06-27 Inhibidores no nucleosidos de la traqnscriptasa inversa

Country Status (18)

Country Link
US (1) US7642277B2 (es)
EP (1) EP1569919B1 (es)
JP (1) JP4550584B2 (es)
KR (1) KR20050084112A (es)
CN (1) CN1720043A (es)
AT (1) ATE554077T1 (es)
AU (1) AU2003287806A1 (es)
BR (1) BR0316385A (es)
CA (1) CA2505033C (es)
CO (1) CO5590958A2 (es)
EA (1) EA200500900A1 (es)
EC (1) ECSP055836A (es)
HR (1) HRP20050502A2 (es)
MX (1) MXPA05005871A (es)
NO (1) NO20052712L (es)
PL (1) PL378198A1 (es)
WO (1) WO2004050643A2 (es)
ZA (1) ZA200503960B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2496565C (en) * 2002-08-23 2013-04-02 Ribapharm Inc. Non-nucleoside reverse transcriptase inhibitors
US7563905B2 (en) 2004-03-12 2009-07-21 Wyeth Triazole derivatives and method of using the same to treat HIV infections
WO2005115147A2 (en) * 2004-05-18 2005-12-08 Merck & Co., Inc. Hiv reverse transcriptase inhibitors
US7517998B2 (en) * 2004-06-01 2009-04-14 Boehringer Ingelheim International Gmbh Non nucleoside reverse transcriptase inhibitors
US20060025480A1 (en) 2004-08-02 2006-02-02 Boehringer Ingelheim International Gmbh Benzoic acid derivatives as non nucleoside reverse transcriptase inhibitors
ME01512B (me) * 2004-08-25 2014-04-20 Ardea Biosciences Inc S-triazolil alfa-merkaptoacetanilida kao inhibitori HIV reversne transkriptaze
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
KR100940058B1 (ko) * 2004-08-25 2010-02-04 아디아 바이오사이언스즈 인크. ＨＩＶ 역 전사 효소의 억제제로서 Ｓ-트리아졸릴 α-메르캅토아세트아닐리드
CA2577144C (en) 2004-09-30 2011-06-21 Boehringer Ingelheim International Gmbh Alkynyl compounds as non-nucleoside reverse transcriptase inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
JP2009519349A (ja) 2005-12-15 2009-05-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を変調する化合物
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
WO2008014199A2 (en) 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 receptor
KR20090069318A (ko) 2006-09-25 2009-06-30 베링거 인겔하임 인터내셔날 게엠베하 Ｃｂ2 수용체를 조절하는 화합물
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP2217565B1 (en) 2007-11-07 2013-05-22 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
ATE541841T1 (de) 2007-11-15 2012-02-15 Boehringer Ingelheim Int Inhibitoren der replikation des human immunodeficiency virus
EP2220046B1 (en) 2007-11-16 2014-06-18 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
SI2217577T1 (sl) 2007-11-27 2014-11-28 Ardea Biosciences, Inc. Nove spojine in sestavki ter metode uporabe
US20110160249A1 (en) 2008-05-23 2011-06-30 Schaab Kevin Murray 5-lipoxygenase-activating protein inhibitor
JP5749162B2 (ja) 2008-07-10 2015-07-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節するスルホン化合物
KR101294872B1 (ko) * 2008-09-04 2013-08-08 아디아 바이오사이언스즈 인크. 요산 수치를 조절하기 위한 화합물, 조성물 및 이들의 사용 방법
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US20110257177A1 (en) * 2008-09-22 2011-10-20 Calcimedica, Inc. Benzylthiotetrazole inhibitors of store operated calcium release
KR20110063438A (ko) 2008-09-25 2011-06-10 베링거 인겔하임 인터내셔날 게엠베하 Ｃｂ2 수용체를 선택적으로 조절하는 설포닐 화합물
JP5643290B2 (ja) 2009-04-09 2014-12-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｈｉｖ複製の阻害薬
CA2760940A1 (en) 2009-05-20 2010-11-25 Ardea Biosciences, Inc. Methods of modulating uric acid levels
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
WO2010147791A1 (en) 2009-06-16 2010-12-23 Boehringer Ingelheim International Gmbh Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor
JP2013505295A (ja) 2009-09-22 2013-02-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を選択的に調節する化合物
EP2523936A1 (en) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
WO2011109324A1 (en) 2010-03-05 2011-09-09 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the cb2 receptor
US8846936B2 (en) 2010-07-22 2014-09-30 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the CB2 receptor
JP6205354B2 (ja) 2011-07-06 2017-09-27 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のための化合物
US8754065B2 (en) 2011-08-16 2014-06-17 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
RU2014110624A (ru) * 2011-09-01 2015-10-10 Ф. Хоффманн-Ля Рош Аг Ингибиторы поли(адф-рибоза)-полимеразы
US9399645B2 (en) 2011-12-20 2016-07-26 Boehringer Ingelheim International Gmbh Inhibitors of HIV replication
CN102675212B (zh) * 2012-05-09 2014-11-05 昆明理工大学 N-取代苯基-2-((1h-苯并咪唑-2-基)巯基)乙酰胺类衍生物及其用途
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
PT2943487T (pt) * 2013-01-09 2016-12-15 Gilead Sciences Inc Heteroarilos de 5 membros e sua utilização como agentes antivirais
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
CN105263913B (zh) * 2013-06-14 2017-12-15 广东东阳光药业有限公司 硫代1,2,4‑三唑衍生物及其制备方法
US10017479B2 (en) 2013-08-02 2018-07-10 Gregory Rosocha Process to make non nucleosidal reverse transcriptase inhibitors (NNRTI) for the treatment of HIV
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
CN104016927B (zh) * 2014-06-19 2016-06-22 山东大学 嘧啶巯乙酰胺类衍生物及其制备方法与应用
US10112929B2 (en) 2015-03-09 2018-10-30 Bristol-Myers Squibb Company Lactams as inhibitors of rock
CN104817509B (zh) * 2015-04-13 2019-05-17 安徽省逸欣铭医药科技有限公司 Lesinurad类似物及其制备方法和医药用途
MX369307B (es) 2016-08-19 2019-11-05 Gilead Sciences Inc Compuestos terapeuticos utiles para tratamiento profilactico o terapeutico de infeccion por virus de inmunodeficiencia humana.
TW202024061A (zh) 2017-08-17 2020-07-01 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
AU2019221568B2 (en) 2018-02-15 2021-04-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating HIV infection
EP3752496B1 (en) 2018-02-16 2023-07-05 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
KR20210033492A (ko) 2018-07-16 2021-03-26 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 캡시드 억제제
CN114727999A (zh) 2019-11-26 2022-07-08 吉利德科学公司 用于预防hiv的衣壳抑制剂
MX2022006489A (es) * 2019-11-29 2022-07-04 Jiangsu Hengrui Medicine Co Derivado de anillo de piridina fusionado, metodo de preparacion y usos farmaceuticos del mismo.
CN110950816B (zh) * 2019-12-13 2021-07-06 山东金城医药化工有限公司 1-(2-二甲基氨基乙基)-5-巯基四唑的合成方法
CN115996925A (zh) 2020-06-25 2023-04-21 吉利德科学公司 用于治疗hiv的衣壳抑制剂
KR20240117588A (ko) 2021-12-03 2024-08-01 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염 치료용 화합물
EP4440702A1 (en) 2021-12-03 2024-10-09 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252815A (en) 1977-04-21 1981-02-24 Mead Johnson & Company Methods of treating cardiovascular diseases with phenyltetrazolyloxy propanolamines
US4186131A (en) 1977-04-21 1980-01-29 Mead Johnson & Company Phenyltetrazolyloxy propanolamines
US4663323A (en) 1978-09-07 1987-05-05 Otsuka Pharmaceutical Co., Ltd. Tetrazole derivatives, anti-ulcer composition containing the same and method for treating ulcers
US4766120A (en) 1978-09-07 1988-08-23 Otsuka Pharmaceutical Company, Limited Tetrazole derivatives, having a further unsaturated heterocyclic ring anti-ulcer composition containing the same and method for treating ulcers
JPS5536447A (en) 1978-09-07 1980-03-14 Otsuka Pharmaceut Co Ltd Butyramide derivative
DE2946432A1 (de) 1979-11-17 1981-06-11 Bayer Ag, 5090 Leverkusen Tetrazolyloxycarbonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
JPH03198048A (ja) 1989-12-27 1991-08-29 Konica Corp ハロゲン化銀写真感光材料
US5124230A (en) 1990-02-02 1992-06-23 Fuji Photo Film Co., Ltd. Silver halide photographic material
IL99731A0 (en) 1990-10-18 1992-08-18 Merck & Co Inc Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them
CA2156420A1 (en) 1993-02-24 1994-09-01 Theresa M. Williams Inhibitors of hiv reverse transcriptase
FR2759369B1 (fr) 1997-02-13 1999-04-02 Essilor Int Nouveaux monomeres mono(thio)(meth)acrylates, composes intermediaires pour la synthese de ces monomeres, compositions polymerisables et polymeres obtenus et leurs applications optiques et ophtalmiques
US6245817B1 (en) 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
AU6267198A (en) * 1997-02-14 1998-09-08 Bayer Corporation Amides as npy5 receptor antagonists
DE69809827D1 (de) 1997-03-31 2003-01-16 Korea Res Inst Chem Tech Chinolinische Sulfid-Derivate als NMDA Rezeptor-Antagonisten und Verfahren zu ihrer Herstellung
US6124306A (en) 1997-09-25 2000-09-26 Pharmacia & Upjohn Company Thioalkyl alpha substituted pyrimidine compounds
US5998411A (en) * 1998-03-17 1999-12-07 Hughes Institute Heterocyclic nonnucleoside inhibitors of reverse transcriptase
NZ508297A (en) 1998-04-27 2002-12-20 Centre Nat Rech Scient 3-(amino- or aminoalkyl)pyridinone derivatives and their use for the treatment of HIV related diseases
IT1305313B1 (it) 1998-07-17 2001-05-04 Colla Paolo 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
US6124324A (en) 1999-06-23 2000-09-26 Hughes Institute Thiophene-ethyl thiourea compounds and use
EP1206568A2 (en) 1999-08-30 2002-05-22 K.U. Leuven Research & Development Target for antiparasitic agents and inhibitors thereof
US6221573B1 (en) 1999-10-27 2001-04-24 Eastman Kodak Company Yellow coupler, photographic element, and process
TWI270547B (en) 2000-06-16 2007-01-11 Boehringer Ingelheim Ca Ltd Non-nucleoside reverse transcriptase inhibitors
AU2001221154A1 (en) 2000-10-19 2002-04-29 Parker Hughes Institute Aromatic and heterocyclic thiazolyl thiourea compounds and use
US6995283B2 (en) 2001-03-02 2006-02-07 Smithkline Beecham Corporation Benzophenones as inhibitors of reverse transcriptase
CA2496565C (en) * 2002-08-23 2013-04-02 Ribapharm Inc. Non-nucleoside reverse transcriptase inhibitors

Also Published As

Publication number Publication date
JP2006514936A (ja) 2006-05-18
ATE554077T1 (de) 2012-05-15
PL378198A1 (pl) 2006-03-06
EA200500900A1 (ru) 2005-12-29
HRP20050502A2 (en) 2006-07-31
WO2004050643A3 (en) 2004-09-10
AU2003287806A1 (en) 2004-06-23
JP4550584B2 (ja) 2010-09-22
CA2505033A1 (en) 2004-06-17
BR0316385A (pt) 2005-10-04
CA2505033C (en) 2011-09-20
MXPA05005871A (es) 2005-08-29
EP1569919A2 (en) 2005-09-07
US7642277B2 (en) 2010-01-05
NO20052712L (no) 2005-06-27
CN1720043A (zh) 2006-01-11
ECSP055836A (es) 2005-08-11
NO20052712D0 (no) 2005-06-06
ZA200503960B (en) 2006-11-29
US20050054639A1 (en) 2005-03-10
WO2004050643A2 (en) 2004-06-17
KR20050084112A (ko) 2005-08-26
EP1569919B1 (en) 2012-04-18

Similar Documents

Publication Publication Date Title
CO5590958A2 (es) Inhibidores no nucleosidos de la traqnscriptasa inversa
NO20090541L (no) Prodrug av cinnamidforbindelse
DE69829875D1 (de) Piperazin-verbindungen und ihre medizinische verwendung
DK0705254T3 (da) Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer
NO20081930L (no) Oksazolforbindelser og farmasoytiske blandinger
NO20070368L (no) Virale polymeraseinhibitorer
MY143245A (en) 4- 2-(cycloalkylamino)pyrimidin-4-yl-(phenyl)-imidazolin-2-one derivatives as p38 map-kinase inhibitors for the treatment of inflammatory diseases
NO20082562L (no) Heterocyklisk forbindelse med inhiberende aktivitet pa 11- -hydroksysteroid-dehydrogenase type 1
NO950533D0 (no) Hydroksyetylaminosulfonamider som er nyttige som retrovirale proteasehemmere
AR055112A1 (es) Fungicidas n-(2-(haloalcoxi) fenil) heteroaril carboxamidas
DE602004028907D1 (de) Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis
WO2004083177A3 (en) Linear chain substituted monocyclic and bicyclic derivatives as factor xa inhibitors
NO20062892L (no) 7-fenylalkyl-substituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)-polymeraseinhibitorer
NO20051600L (no) 1,4-disubstituerte piperidinderivater og anvendelse derav som 11-betaHSD1 inhibitorer
WO2006014282A3 (en) Prodrugs of hiv protease inhibitors
NO20061789L (no) Aminopyridinderivater som induserbare NO-syntaseinhibitorer
SE0103710D0 (sv) Compounds
BRPI0910761A2 (pt) compostos tendo atividade antagonista de receptores npy y5 e composições farmacêuticas compreendendo os mesmos
DK1706414T3 (da) Fremgangsmåde til fluorcytidinderivater
WO2008136378A1 (ja) 新規なスルホンアミド誘導体またはその塩
WO2005058841A3 (en) Hiv protease inhibiting compounds
DE602004023873D1 (de) Verwendung davon
WO2004066952A3 (en) Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases
DK1628968T3 (da) 4-imidazolin-2-on-forbindelser
BR0013409B1 (pt) compostos fungicidas possuindo uma porção flúorvinil ou fluorpropenil-oxifeniloxima e processo para preparação dos mesmos.

Legal Events

Date Code Title Description
FC Application refused